A phase 2 randomized trial in 109 adults with early-stage myeloid malignancies or precursor conditions found that oral vitamin C did not change the primary endpoint of clonal growth rate. Secondary outcomes included differences in inflammatory cytokine trajectories and fewer serious adverse events in the vitamin C group, and exploratory analysis suggested longer overall survival.
Source: Human randomized trial, 109 adults with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies. People were assigned at random to take it or not: the strongest single kind of study for showing cause and effect.
What was found
The primary endpoint, median clonal growth rate, did not differ between the vitamin C group and the placebo group. Secondary outcomes included differences in inflammatory cytokine trajectories. The vitamin C group had fewer serious adverse events (33%) compared to the placebo group (57%). In exploratory analyses, overall survival was significantly longer with vitamin C.
How it was done
The EVITA study was a double-blind, randomized, placebo-controlled, phase 2 trial. It was conducted in Denmark and the United States. Adults with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies not receiving anticancer therapy were randomly assigned to receive oral vitamin C (1000 mg/day) or placebo for 12 months. This was followed by long-term follow-up.
What it does not show
This was a phase 2 trial, which is an early stage of clinical investigation. The finding of longer overall survival was from an exploratory analysis, not a primary outcome, and requires further confirmation. The trial involved 109 participants, which is a relatively small number.
What happens next
A phase 3 trial is warranted.
Who was talking about it
- ScienceDaily: Nutrition on the news (2026-10-03): ScienceDaily reported that a phase 2 trial of vitamin C in people with precancerous or low-risk blood cancers found it was linked to favorable changes in inflammation, fewer serious complications, and fewer deaths. See the post
The source
This is news, reported from the source above. It is not medical advice and not a recommendation. Talk to your doctor or pharmacist before you change any medicine or supplement.